News

Vipergen Establishes Research Partnership with ALK Focused on DNA-Encoded Library (DEL)-Based Drug Discovery for Allergy Immunotherapies

COPENHAGEN, Denmark, November 15, 2021—Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with the allergy company ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF). Under the terms of the agreement, Vipergen will apply its high-fidelity DEL […]

Vipergen Establishes Research Partnership with ALK Focused on DNA-Encoded Library (DEL)-Based Drug Discovery for Allergy Immunotherapies Read More »

BASF and Vipergen accelerate targeted research and development of sustainable crop protection products

Limburgerhof, Germany, and Copenhagen, Denmark, October 21, 2021 – Farmers worldwide are facing the challenge of feeding a growing population while reducing the impact of agriculture on the environment. BASF partners with Vipergen, a global leader in research services, to apply their technology to discover new active ingredients for sustainable crop protection products more efficiently

BASF and Vipergen accelerate targeted research and development of sustainable crop protection products Read More »

Vipergen Establishes Research Partnership with PhoreMost Focused on DNA Encoded Library (DEL)-Based Drug Discovery

COPENHAGEN, Denmark, September 14, 2021—Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with PhoreMost. Under the terms of the agreement, Vipergen will apply its high-fidelity DEL technology platforms to identify novel small-molecule compounds that bind to selected PhoreMost

Vipergen Establishes Research Partnership with PhoreMost Focused on DNA Encoded Library (DEL)-Based Drug Discovery Read More »

Vipergen Establishes Partnership with Anavo Therapeutics to Support Phosphatase-Targeted Discovery Programs

COPENHAGEN, Denmark, May 17, 2021—Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a drug discovery service agreement with Anavo Therapeutics. Under the terms of the agreement, Vipergen will apply its proprietary high-fidelity DNA-encoded library (DEL) technology platforms to provide novel small-molecule drug leads

Vipergen Establishes Partnership with Anavo Therapeutics to Support Phosphatase-Targeted Discovery Programs Read More »

Vipergen strengthens leadership by appointing Dr Leif Kongskov Larsen as Director of Biology and promoting Dr Allan Beck Christensen to Director of Screening Technologies

COPENHAGEN, Denmark, March 17, 2021— Vipergen ApS today announced the appointment of Leif Kongskov Larsen, Ph.D. as Director of Biology, and the promotion of Allan Beck Christensen, Ph.D., to Director of Screening Technology. Dr. Larsen and Dr. Christensen will report directly to Nils Hansen, Ph.D. Vipergen’s CEO. Dr. Larsen and Dr. Christensen will be members

Vipergen strengthens leadership by appointing Dr Leif Kongskov Larsen as Director of Biology and promoting Dr Allan Beck Christensen to Director of Screening Technologies Read More »

Vipergen Publishes First Technology for Screening DNA-Encoded Small-Molecule Libraries (DELs) Inside Living Cells

Vipergen Publishes First Technology for ScreeningDNA-Encoded Small-Molecule Libraries (DELs) Inside Living Cells — Vipergen’s Cellular Binder Trap Enrichment® (cBTE) technology provides a robust systemto accelerate and improve drug discovery — — Study published in Journal of the American Chemical Society — COPENHAGEN, Denmark, February 17, 2021— Vipergen ApS announced today a published study describing a

Vipergen Publishes First Technology for Screening DNA-Encoded Small-Molecule Libraries (DELs) Inside Living Cells Read More »